"ITPKB", c'est le nom de l'enzyme dont les mécanismes d'action spécifiques dans l'aggravation de l'état des patients atteints de la maladie d'Alzheimer sont désormais mieux connus grâce à une étude ULg-ULB parue dans Brain. Les développements de cette étude sont prometteurs.
The Lumo Lift is the second product from startup Lumo BodyTech, and the second to help users with their posture. The Lumo Back was the first, and it raised around $200,000 in 40 days on Kickstarter. This time, Lumo opted to do the crowdfunding themselves, and the trajectory of the latest device has been quite different: Lumo Lift is at over $900,000 raised as of this writing, just under a month into the pre-order period.
Des scientifiques de l'université technologique de Toyohashi et du NCGG (Centre national pour la gériatrie et la gérontologie) ont dévoilé le 21 janvier une méthode de diagnostic de la maladie d'Alzheimer et d'autres maladies, utilisable chez soi à partir d'une simple goutte de sang. En utilisant un capteur d'image semi-conducteur, les chercheurs peuvent détecter un léger changement de potentiel électrique qui survient quand les peptides amyloïdes-β, une protéine que l'on relie à la maladie d'Alzheimer, interagissent avec des anticorps spécifiques.
A recent report by CB Insights surveyed startup casualties in the past few years and revealed that more than half (55 percent) of startups that failed last year had raised $1 million or less. It also calculated that they had an average life span of 20 months from the last funding round if they couldn’t secure additional funding or find a buyer. Not surprisingly, most were focused on Internet technology, though mobile startups were among the casualties.
Researchers at Carnegie Mellon University have created ingestible batteries, that could make internal devices a possibility.
While wearable technology is bringing smart devices even closer to home, another emerging field is the development of electronics that actually sit inside our bodies. We recently reported on TruTag — ingestible nanoscale electronic tags that could help tackle pharma fraud — and now researchers at Carnegie Mellon University have created edible batteries, that could be used to power biodegradable devices located inside the body.
Using tiny biodegradable particles to disrupt the body’s normal immune response after a heart attack could help save patients from tissue damage and certain long-term health problems that often follow. Researchers have shown that injecting such particles into mice within 24 hours of a heart attack not only significantly reduces tissue damage, but also results in those mice having stronger cardiac function 30 days later. The inventors of the new technology now plan to pursue human trials.
Health Catalyst thinks that every hospital will need a data warehouse to organize and visualize its data.
The bet may already paying off. The Salt Lake City-based company closed $41 million in funding today, which closely follows a $33 million round in early January. This brings its total funding amount to just shy of $100 million.
Health Catalyst, which was formerly known as Healthcare Quality Catalyst, has provided medical data warehousing for hospitals and health systems since 2008. More than a dozen large hospitals have already bought the software, and Indiana University Health, Kaiser Permamente (through its venture arm) and Partners HealthCare invested in the company.
A small group of special individuals could act as an early warning system for the next epidemic. Their special power? Super-spreading disease.
When the next highly infectious disease begins to spread through a densely populated metropolitan area, the authorities will have a only short period of time to put in place emergency measures to prevent an epidemic. Hit this window of opportunity and the number of casualties could be relatively small. Miss it and the number could be frighteningly large.
So it’s no surprise that there is significant interest in finding efficient ways to spot the early cases. The stakes could hardly be larger.
For the past decade, former Apple chief executive John Sculley has been taking on the problem of reforming health care through new technologies.
And now that the Obamacare rollout is in full effect, Sculley is betting on the Sunrise, Fla.-based MDLive to bring the practice of medicine into the modern area.
Since 2008, eight patients have been given a new chance at life when surgeons replaced their badly damaged tracheas with man-made versions. This highly experimental technology is now moving from research labs to a manufacturing facility as a Boston-area company prepares to produce the scaffolds for growing the synthetic organs on a large scale.
Harvard Apparatus Regenerative Technology, or HART, is testing its synthetic trachea system in Russia and has plans for similar tests in the European Union this year. The company is working with the U.S. Food and Drug Administration to set up a trial in the United States as well.
